About us

The Pharmacogenomics in Childhood Asthma (PiCA) consortium is a research consortium that has been established in December 2013 by prof. dr. Anke-Hilse Maitland van der Zee and dr. Susanne Vijverberg to bring together asthma studies that have genetic data and treatment outcome measures. Asthma is the most common chronic disease in childhood. Although it cannot be cured, effective treatments are available. However, there is a large variability in treatment response which is partly due to genetic variances.

Studies are eligible to participate in the PiCA consortium if:

  • Data on asthmatic children or young persons have been collected;
  • DNA samples have been collected or can be collected;
  • Data are collected on asthma drug use;
  • Data are collected on treatment outcome.

PiCA is a growing consortium. Currently, over 20 studies participate in the PiCA consortium.

For more information on the rationale and design of the consortium see:

Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. Farzan et al. Pharmacogenomics 2017; 18(10):931-943. 

Geef een reactie

Het e-mailadres wordt niet gepubliceerd.

De volgende HTML-tags en -attributen zijn toegestaan: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>